scholarly journals Metachronous Gastric Cancer Occurring after Endoscopic Resection of Early Gastric Cancer

2020 ◽  
Vol 20 (4) ◽  
pp. 295-299
Author(s):  
Gwang Ha Kim
Keyword(s):  
Gastric Cancer ◽  
Endoscopic Resection ◽  
Early Stage ◽  
Long Term Outcomes ◽  
En Bloc ◽  
Gastric Cancers ◽  
Metachronous Gastric Cancer ◽  
H Pylori ◽  
Surveillance Endoscopy

Endoscopic resection (ER) has been widely used as a curative treatment for early gastric cancers (EGCs). Especially endoscopic submucosal dissection has several merits such as high en bloc and curative resection rates for EGCs and preservation of the entire stomach. However, ER has the inevitable limitation that the possibility of newly developing gastric cancers in the preserved stomach is still present. Metachronous gastric cancer (MGC) is defined as a newly developed gastric cancer occurring at a previously uninvolved site ≥1 year after the index ER of EGCs. The incidence of MGC is 3.3~15.6% and increases over time after ER. Old age, male sex, current smoking, severe atrophy and intestinal metaplasia, persistent Helicobacter pylori (H. pylori) infection, differentiated-type histology, and multiple initial gastric cancers are risk factors of MGC. As H. pylori eradication could reduce the risk of MGC after ER of EGCs, H. pylori eradication is strongly recommended for the prevention of MGC after ER of EGCs. Most MGCs are found at an early stage on regular surveillance endoscopy after ER and successfully treated with ER, with excellent long-term outcomes.

Long-term outcomes after noncurative endoscopic resection of early gastric cancer: the optimal time for additional endoscopic treatment

2018 ◽  
Vol 87 (4) ◽  
pp. 1003-1013.e2 ◽  
Author(s):  
Mi Young Jeon ◽  
Jun Chul Park ◽  
Kyu Yeon Hahn ◽  
Sung Kwan Shin ◽  
Sang Kil Lee ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Early Gastric Cancer ◽  
Endoscopic Resection ◽  
Endoscopic Treatment ◽  
Optimal Time ◽  
Long Term Outcomes

Sa1586 Long-Term Outcomes of Endoscopic Resection for Undifferentiated Early Gastric Cancer

2013 ◽  
Vol 77 (5) ◽  
pp. AB258-AB259
Author(s):  
Yong Hoon Kim ◽  
Han Ho Jeon ◽  
Jie-Hyun Kim ◽  
Yong Chan Lee ◽  
Hyuk Lee ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Early Gastric Cancer ◽  
Endoscopic Resection ◽  
Long Term Outcomes ◽  
Undifferentiated Early Gastric Cancer

H. Pylori eradication for the prevention of metachronous gastric cancer after endoscopic resection of early gastric cancer

2001 ◽  
Vol 120 (5) ◽  
pp. A744
Author(s):  
Mototsugu Kato ◽  
Kaku Hokari ◽  
Jun Ishizuka ◽  
Takuji Mizushima ◽  
Yoshito Komatsu ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Early Gastric Cancer ◽  
Endoscopic Resection ◽  
Metachronous Gastric Cancer ◽  
H Pylori

Comparison of Long-Term Outcomes After Non-curative Endoscopic Resection in Older Patients with Early Gastric Cancer

2017 ◽  
Vol 24 (9) ◽  
pp. 2624-2631 ◽  
Author(s):  
Jeung Hui Pyo ◽  
Hyuk Lee ◽  
Byung-Hoon Min ◽  
Jun Haeng Lee ◽  
Kyoung-Mee Kim ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Early Gastric Cancer ◽  
Endoscopic Resection ◽  
Older Patients ◽  
Long Term Outcomes

scholarly journals Helicobacter pylori Infection following Endoscopic Resection of Early Gastric Cancer

2019 ◽  
Vol 2019 ◽  
pp. 1-6
Author(s):  
Lan Li ◽  
Chaohui Yu
Keyword(s):  
Gastric Cancer ◽  
Helicobacter Pylori ◽  
Early Gastric Cancer ◽  
Endoscopic Resection ◽  
Precancerous Lesions ◽  
Cost Effective ◽  
Reduce Healthcare Cost ◽  
Metachronous Gastric Cancer ◽  
H Pylori ◽  
Meta Analyses

The role of Helicobacter pylori (H. pylori) infection in patients following endoscopic resection of early gastric cancer (EGC) remains unclear. This article presents a review of literature published in the past 15 years. H. pylori‐mediated persistent methylation levels are associated with the development of metachronous gastric cancer. The methylation of certain specific genes can be used to identify patients with a high risk of metachronous gastric cancer even after H. pylori eradication. H. pylori eradication after endoscopic resection should be performed as early as possible for eradication success and prevention of metachronous precancerous lesions. Although whether the eradication of H. pylori could prevent the development of metachronous cancer after endoscopic resection is controversial, several meta‐analyses concluded that H. pylori eradication could reduce the incidence of metachronous gastric cancer significantly. In addition, H. pylori eradication in gastric cancer survivors after endoscopic resection could reduce healthcare cost and save lives in a cost‐effective way. Taken together, H. pylori eradication after endoscopic resection of EGC is recommended as prevention for metachronous precancerous lesions and metachronous gastric cancer.

scholarly journals Statin Use Decreases the Risk of Metachronous Gastric Cancer in Patients without Helicobacter pylori Infection

Cancers ◽  
2021 ◽  
Vol 13 (5) ◽  
pp. 1020
Author(s):  
Tae Jin Kwon ◽  
Tae Jun Kim ◽  
Hyuk Lee ◽  
Yang Won Min ◽  
Byung-Hoon Min ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Endoscopic Resection ◽  
Cox Regression ◽  
Defined Daily Dose ◽  
Cox Regression Analysis ◽  
Daily Dose ◽  
Metachronous Gastric Cancer ◽  
H Pylori ◽  
Statin Use

Previous studies have shown that statins reduce the risk of gastric cancer; however, their role has not been adequately studied in patients without Helicobacterpylori infection. We aimed to investigate whether statins reduced the risk of metachronous gastric cancer (GC) in H. pylori-negative patients who underwent endoscopic resection for early gastric cancer (EGC). Retrospective data of 2153 patients recruited between January 2007 and December 2016, with no H. pylori infection at baseline, who underwent resection for EGC, were analyzed. Metachronous GC was defined as a newly developed GC at least 1 year after endoscopic resection. Patients who used statins for at least 28 days during the follow-up period were considered as statin users. During a median follow-up of 5 years (interquartile range, 3.5–6.2), metachronous GC developed in 165 (7.6%) patients. In the multivariate Cox regression analysis, statin use was an independent factor associated with GC recurrence (adjusted hazard ratio (HR), 0.46; 95% confidence interval (CI), 0.26–0.82). Moreover, the risk of GC reduced with increasing duration (<3 years: HR 0.40, 95% CI 0.14–1.13; ≥3 years: HR 0.21, 95% CI 0.05–0.90; p trend = 0.011) and the dose of statin (cumulative defined daily dose (cDDD) < 500: HR 0.45, 95% CI 0.16–1.28; cDDD ≥ 500: HR 0.19, 95% CI 0.04–0.80; p trend = 0.008) in the propensity score-matched cohort. Statin use was associated with a lower risk of GC recurrence in H. pylori-negative patients with resected EGC in a dose-response relationship.

Sign in / Sign up

Export Citation Format

Share Document